Elotuzumab

354,00 

Elotuzumab (Empliciti™) is a humanized IgG1 monoclonal antibody developed by Bristol-Myers Squibb (BMS) and AbbVie. Elotuzumab binds to the cell surface receptor signaling lymphocytic activation molecule F7 (SLAMF7), which is selectively expressed on myeloma cells and natural killer cells, leading to antibody-dependent cellular cytotoxicity and direct natural killer cell activation. Markham, A. Elotuzumab: First Global Approval. Drugs 76, 397–403 (2016).

Product Concentration [mg/mL] Volume per Vial [µL] Quantity per vial [mg] Storage [°C] Original therapeutic expiry date [see Note 1] CoA [see Note 2] PriceQuantityTotal
2524062-8°/-80°04/2023no 354,00 
-
+
354,00 
spinner

Description

Additional information

WeightN/A
Product Concentration [mg/mL]

25

Volume per Vial [µL]

240

Quantity per vial [mg]

6

Storage [°C]

2-8°/-80°

Therapeutic molecule

Elotuzumab

Original therapeutic expiry date [see Note 1]

04/2023

CoA [see Note 2]

no

Antigen

SLAM